Leerink Swann maintained an Outperform rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) and raised its price target to $80.00 (from $57.59) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE